GelMEDIX: $13 Million Seed Funding Closed For Vision Restoration Biotechnology Platform
By Amit Chowdhry ● Today at 12:52 PM
GelMEDIX, a biotechnology company developing regenerative therapies to restore vision, has completed a $13 million seed financing round led by Safar Partners, with participation from HTL Biotechnology, Beacon Angels, TiE Boston Angels, Boston Harbor Angels, and other investors. The company will use the proceeds to advance its lead program, GMX-101, a retinal pigment epithelial cell therapy designed to treat late-stage Geographic Atrophy, and to further develop its proprietary injectable hydrogel scaffold platform.